These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8369102)

  • 61. Effects of long-term L-dopa therapy on carbohydrate metabolism in patients with Parkinson's disease.
    Rosati G; Maioli M; Aiello I; Farris A; Agnetti V
    Eur Neurol; 1976; 14(3):229-39. PubMed ID: 1278195
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [The deterioration of patients with parkinsonism treated with L-dopa].
    Guillard A
    Nouv Presse Med; 1975 Oct; 4(35):2503-6. PubMed ID: 1196872
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Progression of Parkinson's disease following thalamic deep brain stimulation for tremor.
    Tarsy D; Scollins L; Corapi K; O'Herron S; Apetauerova D; Norregaard T
    Stereotact Funct Neurosurg; 2005; 83(5-6):222-7. PubMed ID: 16534254
    [TBL] [Abstract][Full Text] [Related]  

  • 64. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group.
    Ghika J; Gachoud JP; Gasser U
    Clin Neuropharmacol; 1997 Apr; 20(2):130-9. PubMed ID: 9099465
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients.
    Katayama Y; Kasai M; Oshima H; Fukaya C; Yamamoto T; Ogawa K; Mizutani T
    J Neurosurg; 2001 Aug; 95(2):213-21. PubMed ID: 11780890
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Lack of an effect of melatonin on the basal and L-dopa stimulated growth hormone secretion in men.
    Weinberg U; Weitzman ED; Horowitz ZD; Burg AC
    J Neural Transm; 1981; 52(1-2):117-21. PubMed ID: 7288433
    [TBL] [Abstract][Full Text] [Related]  

  • 68. An analysis of tremor--alteration of parkinsonian tremor by L-dopa and surgical treatment.
    Yoshida M
    Kurume Med J; 1979; 26(3):261-72. PubMed ID: 529758
    [No Abstract]   [Full Text] [Related]  

  • 69. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The long-term results of stereotaxic surgery and L-dopa therapy in patients with Parkinson's disease. A 10-year follow-up study.
    Kelly PJ; Gillingham FJ
    J Neurosurg; 1980 Sep; 53(3):332-7. PubMed ID: 6999132
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Both L-DOPA and HFS-STN restore the enhanced group II spinal reflex excitation to a normal level in patients with Parkinson's disease.
    Marchand-Pauvert V; Gerdelat-Mas A; Ory-Magne F; Calvas F; Mazevet D; Meunier S; Brefel-Courbon C; Vidailhet M; Simonetta-Moreau M
    Clin Neurophysiol; 2011 May; 122(5):1019-26. PubMed ID: 20943434
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase shifts in the circadian rhythm in plasma concentrations of melatonin in rams induced by a 1-hour light pulse.
    Maeda KI; Lincoln GA
    J Biol Rhythms; 1990; 5(2):97-106. PubMed ID: 2133129
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Changes in movement-related cortical potentials in Parkinson's patients before and after treatment with levodopa].
    Feve AP; Bathien N; Rondot P
    Neurophysiol Clin; 1991 May; 21(2):105-19. PubMed ID: 1921938
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Circadian Regulation and Its Disorders in Parkinson's Disease Patients. Part 2. Experimental Models, Alpha-Synuclein and Melatonin.].
    Ukraintseva YV; Kovalzon VM
    Fiziol Cheloveka; 2016 Sep; 42(5):108-120. PubMed ID: 29932556
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical criteria for the switch of treatment strategies in Parkinson's disease.
    Schoenfeld MA; Pantelie CM; Schwartz B
    Clin Neurol Neurosurg; 2003 Sep; 105(4):241-4. PubMed ID: 12954538
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Levodopa Is a Double-Edged Sword for Balance and Gait in People With Parkinson's Disease.
    Curtze C; Nutt JG; Carlson-Kuhta P; Mancini M; Horak FB
    Mov Disord; 2015 Sep; 30(10):1361-70. PubMed ID: 26095928
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Juvenile Parkinson's disease and its response to L-dopa therapy.
    Askenasy JJ; Mendelson L; Keren O; Braun Z
    J Neural Transm Park Dis Dement Sect; 1990; 2(1):23-30. PubMed ID: 2357269
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study.
    Brooks DJ; Playford ED; Ibanez V; Sawle GV; Thompson PD; Findley LJ; Marsden CD
    Neurology; 1992 Aug; 42(8):1554-60. PubMed ID: 1641153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.